SCHEMBL3133666

SCHEMBL3133666

CC(C)(C)C1CCC(c2ccccc2O)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.41
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CDC25B P30305 1/20 0.39
HTR2C P28335 2/20 0.39
HTR2A P28223 1/20 0.39
HTR2B P41595 1/20 0.39
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
SLC18A3 Q16572 2/20 0.36
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
ALPG P10696 1/20 0.36
KDM4E B2RXH2 1/20 0.36
MAPT P10636 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD11B1 P28845 1/20 0.35
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31153232 0.84 CHRNB2 (0.46) GLAMEN1KMT2ACDC25BALDH1A1
SCHEMBL929830 0.84 MEN1 (0.50) MEN1KMT2AHTR2CHTR2AHTR2B
SCHEMBL3992205 0.84 MEN1 (0.50) MEN1KMT2AHTR2CHTR2AHTR2B
SCHEMBL11093594 0.81 HTR2A (0.42) MEN1KMT2AHTR2CHTR2AHTR2B
SCHEMBL15891136 0.80 GLA (0.38) GLACDC25BALDH1A1SLC18A3ALPL
SCHEMBL5428628 0.79 ESR2 (0.48) MEN1KMT2AHTR2CHTR2AHTR2B
SCHEMBL28428015 0.79 ESR2 (0.48) MEN1KMT2AHTR2CHTR2AHTR2B
SCHEMBL4848442 0.78 GLA (0.38) GLAMEN1KMT2ACDC25BHTR2C
Methane SCHEMBL27694970 0.77 ESR2 (0.47) MEN1KMT2AHTR2CHTR2AHTR2B
SCHEMBL1509720 0.76 ESR2 (0.47) MEN1KMT2AHTR2CHTR2AHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2137193-B1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI SA (FR) 2017-08-09 EP disclosed
CN-104447792-A Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI AVENTIS 2015-03-25 CN disclosed
US-8642603-B2 Substituted dihydro and tetrahydro oxazolopyrimidinones, preparation and use thereof SANOFI (FR) 2014-02-04 US disclosed
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2010-03-25 US disclosed
CN-101675060-A Substituted dihydro and tetrahydro oxazolopyrimidinones, their preparation and use SANOFI AVENTIS 2010-03-17 CN disclosed
EP-2137193-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF Sanofi-Aventis (FR) 2009-12-30 EP disclosed
WO-2008112483-A2 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF SANOFI-AVENTIS (FR) 2008-09-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100075994-A1 SUBSTITUTED DIHYDRO AND TETRAHYDRO OXAZOLOPYRIMIDINONES, PREPARATION AND USE THEREOF GRM2, GRM1, GRIN2C GLA 4572/4885MEN1 3249/4885KMT2A 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.